ALNYLAM PHARMACEUTICALS, INC. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 42/100
What the filing says
Alnylam reported Q2 2026 net product revenues of $1,172M (74% YoY growth), with AMVUTTRA at $1,012M (106% growth) and ONPATTRO at $18M. The company lowered full-year 2026 TTR revenue guidance from $4,400-$4,700M to $4,200-$4,500M, citing normalization of second-line ATTR-CM demand after early pent-up demand. Total 2026 net product revenue guidance reduced from $4,900-$5,300M to $4,700-$5,100M. Cash position strengthened to $3.3B from $2.9B at year-end 2025.
Why this rating
Guidance reduction signals AMVUTTRA launch deceleration; material but company's $42.6B market cap absorbs it. Pipeline and cash position remain strong.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.